Phospho-RPS6KB1 (S427) Antibody

What is RPS6KB1 and what is the significance of its phosphorylation at Ser427?

RPS6KB1 (Ribosomal Protein S6 Kinase Beta-1) is a serine/threonine protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients. It promotes cell proliferation, cell growth, and cell cycle progression by regulating protein synthesis through phosphorylation of targets including EIF4B, RPS6, and EEF2K .

The phosphorylation at Ser427 is located in the autoinhibitory domain (amino acids 424-525) and is critical for RPS6KB1 activation. RPS6KB1 activation is initiated by mTOR/raptor-mediated phosphorylation of Thr389, followed by multiple phosphorylation events in the autoinhibitory domain, including Ser427 . Quantitative phosphoproteomic studies have shown that rapamycin treatment significantly reduces Ser427 phosphorylation (to a ratio of 0.09 compared to control), indicating its regulation by the mTOR pathway .

How does Phospho-RPS6KB1 (S427) relate to the mTOR signaling pathway?

Phospho-RPS6KB1 (S427) serves as a direct downstream indicator of mTORC1 activity. When mTORC1 is active, it promotes phosphorylation of multiple sites on RPS6KB1, including Ser427 . The activation sequence of RPS6KB1 appears to begin with phosphorylation in the autoinhibitory domain (424-525), where Ser427 is located .

Within the signaling cascade, active RPS6KB1 then phosphorylates numerous substrates involved in protein synthesis, including:

• Ribosomal protein S6 at positions S235, S236, S240, and S244

• Translation initiation factor EIF4B

• Translation elongation via EEF2K inhibition

• Negative regulators like PDCD4

The phosphorylation status of Ser427 thus serves as a biomarker for active mTOR signaling and can be used to monitor the effects of mTOR-targeting drugs or nutritional interventions.

What techniques can be used with Phospho-RPS6KB1 (S427) antibody?

Based on validated applications from multiple sources, Phospho-RPS6KB1 (S427) antibody can be utilized in:

The antibody has been validated with human, mouse, and rat samples, with predicted cross-reactivity to other species including chicken, dog, pig, cow, horse, and rabbit .

How can I optimize Western blot protocols when using Phospho-RPS6KB1 (S427) antibody?

For optimal Western blot results with Phospho-RPS6KB1 (S427) antibody:

• Sample preparation:

  • Use fresh cell lysates or flash-frozen tissues

  • Include phosphatase inhibitors in lysis buffer to preserve phosphorylation status

  • Load approximately 30 μg total protein per lane

• Running conditions:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Include pre-stained molecular weight markers

• Transfer and blocking:

  • Transfer to PVDF or nitrocellulose membranes

  • Block with 5% BSA in TBST (not milk, as it contains phosphatases)

• Antibody incubation:

  • Dilute primary antibody 1:500-2000 in 5% BSA/TBST

  • Incubate overnight at 4°C with gentle agitation

  • Use appropriate anti-rabbit IgG secondary antibody (HRP-conjugated or fluorescent)

• Visualization:

  • Both chemiluminescence and fluorescent detection (IRDye800CW) systems work well

  • ECL substrates with enhanced sensitivity are recommended for detecting low abundance phosphoproteins

• Controls:

  • Include K562 cell lysates as positive control

  • Use rapamycin-treated samples (0.55 μM, 15 min) as negative control

What are the recommended positive and negative controls for validating Phospho-RPS6KB1 (S427) antibody specificity?

For rigorous validation of Phospho-RPS6KB1 (S427) antibody specificity:

Positive Controls:

• K562 cell lysates (human chronic myelogenous leukemia cell line) consistently show strong signals

• MCF-7 cells (human breast cancer cell line) show detectable levels

• PMA-treated (200 nM, 15 minutes) Jurkat cells show increased phosphorylation of downstream targets

Negative Controls:

• Rapamycin treatment (0.55 μM for 15 minutes) reduces Ser427 phosphorylation by approximately 91%

• LY294002 (PI3K inhibitor, 50 μM, 2.5 hours) treated cells show reduced phosphorylation

• Lambda phosphatase-treated lysates should show complete signal elimination

• Peptide competition using the immunizing phosphopeptide KF(p-S)FE

• Isotype control using rabbit IgG at equivalent concentration

Additional Validation Methods:

• siRNA knockdown of RPS6KB1

• Comparison of signal between wild-type and RPS6KB1 knockout tissues

• Dual recognition methods like Proximity Ligation Assay using antibodies against total RPS6KB1 and phospho-Ser427

How does rapamycin treatment affect the phosphorylation status of RPS6KB1 at Ser427?

Rapamycin treatment has a profound effect on RPS6KB1 phosphorylation at Ser427:

• Quantitative impact: Phosphoproteomic studies show that 15-minute treatment with 0.55 μM rapamycin reduces Ser427 phosphorylation to a ratio of 0.09 compared to untreated controls, representing a 91% reduction .

• Time course: The effect begins rapidly, with significant dephosphorylation occurring within 15 minutes of treatment.

• Mechanism: Rapamycin forms a complex with FKBP12 that binds to mTORC1, preventing its kinase activity. This inhibition blocks mTORC1-mediated phosphorylation of multiple sites on RPS6KB1 .

• Broader effects: Rapamycin causes dephosphorylation of not only Ser427 but also other RPS6KB1 sites, including Ser452 (reduced to a ratio of 0.26) .

• Downstream consequences: The inhibition of RPS6KB1 phosphorylation leads to reduced phosphorylation of downstream targets such as RPS6 at positions S235, S236, S240, and S244 .

This rapamycin-induced dephosphorylation pattern makes it an excellent negative control for antibody validation and an important tool for studying mTOR-dependent phosphorylation events.

How does ammonia-induced autophagy affect RPS6KB1 phosphorylation compared to rapamycin-induced autophagy?

Ammonia and rapamycin induce autophagy through distinct mechanisms with differential effects on RPS6KB1 phosphorylation:

Rapamycin-induced autophagy:

• Directly inhibits mTORC1 activity

• Causes significant dephosphorylation of RPS6KB1 at Ser427 (to a ratio of 0.09)

• Reduces phosphorylation of downstream targets like RPS6

• Acts through an mTOR-dependent mechanism

Ammonia-induced autophagy:

• Does not inhibit mTORC1 activity

• Maintains or slightly increases RPS6KB1 phosphorylation levels

• Preserves phosphorylation of RPS6 at Ser235 and Ser240

• Appears to work through an mTOR-independent mechanism

These differences highlight that autophagy can be induced through multiple pathways. Quantitative phosphoproteomic studies suggest that ammonia-induced autophagy may involve:

• Upregulation of AMPK signaling

• Activation of the unfolded protein response (UPR)

• Increased MAPK3 activity

• Regulation of proteins involved in Rho signal transduction

This distinction is critical for researchers studying autophagy regulation in various physiological and pathological contexts, particularly in cancer cells where ammonia is a byproduct of glutamine catabolism.

What is the relationship between GSK3B and RPS6KB1 phosphorylation in the context of autophagy regulation?

The relationship between GSK3B and RPS6KB1 phosphorylation reveals a complex regulatory network in autophagy control:

• GSK3B as an autophagy regulator: GSK3B has been implicated in mediating proteasomal degradation of mTOR and related components, which can induce autophagy .

• Phosphorylation motifs: GSK3B preferentially phosphorylates substrates with the motif S/TxxxS/T(p), where the fourth serine/threonine is often pre-phosphorylated by another kinase (priming phosphorylation) .

• Interconnection with stress kinases: Phosphoproteomic studies suggest that stress kinases like MAPK14 might prime phosphorylation sites for subsequent GSK3B phosphorylation. For example, two phosphosites on mTOR upregulated by ammonia are predicted to be substrates of MAPK14 and GSK3B .

• Protein degradation pathway: GSK3B often phosphorylates substrates of FBXW7, an F-Box protein that acts as a substrate specificity factor for cullin RING ubiquitin ligases. FBXW7 can bind to the HEAT domain of mTOR, potentially marking it for degradation .

• Impact on RPS6KB1: While GSK3B doesn't directly target Ser427 of RPS6KB1, its regulation of mTOR can indirectly affect RPS6KB1 phosphorylation status.

In ammonia-induced autophagy, a hypothesized mechanism is that MAPK14 primes phosphorylation of mTOR, followed by GSK3B phosphorylation, leading to FBXW7 binding and subsequent ubiquitination and proteasomal degradation of mTOR components . This would represent an mTOR regulation pathway distinct from rapamycin's direct inhibition mechanism.

What is the difference between RPS6KB1 (S6K1) and RPS6KB2 (S6K2) in terms of function and regulation?

RPS6KB1 (S6K1) and RPS6KB2 (S6K2) show both overlapping and distinct functions:

Size and structural differences:

• Both are serine/threonine kinases in the AGC kinase family

• They share similar domain structures but have distinct regulatory regions

Phenotypic effects in knockout models:

• S6k1-/- mice exhibit markedly smaller body size

• S6k2-/- mice are slightly larger than wild-type

• Single knockouts of either gene produce viable mice

• Double knockout (S6k1/2-/-) results in perinatal lethality, indicating partial functional redundancy but also unique roles

Substrate specificity:

• Both kinases phosphorylate ribosomal protein S6

• S6K2 appears to play a dominant role in S6 phosphorylation

• They may have different preferences for other substrates in the translation machinery

Compensatory mechanisms:

• In the absence of both S6K1 and S6K2, phosphorylation of S6 at S235 and S236 is maintained by 90-kDa ribosomal protein S6 kinases (RSKs)

• This indicates parallel pathways for controlling translation

Regulation:

• Both are regulated by mTORC1, but may respond differently to various upstream signals

• They may localize to different subcellular compartments, affecting their access to substrates and regulators

These differences are important considerations when designing experiments targeting S6K signaling or interpreting phenotypes of genetic models.

What are the effects of RPS6KB1 knockout on S6 phosphorylation and what compensatory mechanisms exist?

RPS6KB1 knockout has nuanced effects on S6 phosphorylation with several compensatory mechanisms:

Direct effects on S6 phosphorylation:

• RPS6KB1 knockout reduces but does not eliminate phosphorylation of ribosomal protein S6

• Primarily affects phosphorylation at positions S240/S244, with partial effects on S235/S236

Primary compensatory mechanism - S6K2:

• RPS6KB2 (S6K2) provides the primary compensation in S6K1 knockout models

• S6K2 may have a dominant role in S6 phosphorylation under normal conditions

• The combined actions of S6K1 and S6K2 are required for maximum S6 phosphorylation

Secondary compensatory mechanisms:

• Even in double knockout (S6k1/2-/-) cells, phosphorylation of S6 at S235 and S236 persists

• This residual phosphorylation is maintained by 90-kDa ribosomal protein S6 kinases (RSKs)

• RSKs are activated by the MAPK/ERK pathway rather than mTOR, providing an alternative input

Functional implications:

• The partial maintenance of S6 phosphorylation explains why single knockout models remain viable

• The complex compensation network highlights the importance of S6 phosphorylation for cellular function

• These mechanisms ensure robustness in the translational control system

Understanding these compensatory pathways is crucial when using genetic models to study mTOR signaling and when developing therapeutic strategies targeting this pathway.

How can Phospho-RPS6KB1 (S427) antibody be used in multiplexed phosphoproteomic studies?

Phospho-RPS6KB1 (S427) antibody can be integrated into several multiplexed phosphoproteomic approaches:

SILAC-based quantitative phosphoproteomics:

• Stable Isotope Labeling with Amino acids in Cell culture (SILAC) enables comparison of phosphorylation levels across different treatments

• Cells are labeled with light, medium, or heavy isotopes of arginine and lysine

• After treatment (e.g., rapamycin vs. ammonia vs. control), lysates are combined and processed together

• Phosphopeptides are enriched using techniques like titanium dioxide (TiO2) chromatography

• Mass spectrometry analysis can quantify thousands of phosphorylation sites simultaneously, including RPS6KB1 Ser427

Antibody-based enrichment strategies:

• Phospho-RPS6KB1 (S427) antibody can be used for immunoprecipitation of phosphorylated RPS6KB1

• The immunoprecipitated material can be analyzed by mass spectrometry to identify co-regulated proteins

• This approach is particularly useful for studying protein complexes associated with active RPS6KB1

Proximity Ligation Assay (PLA):

• Combines two antibodies—one against total RPS6KB1 and one against phospho-Ser427

• When both antibodies bind in close proximity, they generate a fluorescent signal

• Each visible dot represents a single phosphorylated protein molecule

• This enables in situ visualization and quantification of phosphorylation events at single-molecule resolution

Multiplexed immunofluorescence:

• Phospho-RPS6KB1 (S427) antibody can be combined with antibodies against other phosphoproteins

• Using spectrally distinct fluorophores allows simultaneous detection of multiple phosphorylation events

• This is particularly valuable for studying pathway cross-talk

These advanced techniques allow researchers to place RPS6KB1 phosphorylation in the broader context of cellular signaling networks and to understand its dynamics in various physiological and pathological conditions.

What are the best applications of Phospho-RPS6KB1 (S427) antibody in cancer research?

Phospho-RPS6KB1 (S427) antibody offers several valuable applications in cancer research:

Monitoring mTOR pathway activation in tumors:

• RPS6KB1 Ser427 phosphorylation serves as a downstream biomarker for mTORC1 activity

• IHC analysis of tumor sections can reveal heterogeneous mTOR activation patterns

• This information can help stratify patients for targeted therapies

Evaluating response to mTOR inhibitors:

• Tracking Ser427 phosphorylation provides a direct readout of drug efficacy

• Western blot analysis can quantify the degree of pathway inhibition achieved

• Flow cytometry with phospho-specific antibodies enables single-cell analysis of drug response

Resistance mechanism studies:

• In tumors resistant to mTOR inhibitors, persistent RPS6KB1 phosphorylation may indicate bypass pathways

• Combinatorial staining with markers of alternative pathways can identify specific resistance mechanisms

• Time-course experiments can reveal rapid vs. delayed reactivation patterns

Cross-talk with other oncogenic pathways:

• Proximity Ligation Assay (PLA) can detect interactions between phosphorylated RPS6KB1 and other signaling proteins

• Co-staining with markers of the MAPK pathway, PI3K pathway, or stress responses provides insights into network rewiring in cancer

Preclinical model validation:

• Confirming pathway modulation in PDX (patient-derived xenograft) models

• Validating genetic models with altered mTOR pathway components

• Correlating phosphorylation patterns with tumor growth, metabolism, and treatment response

These applications are particularly relevant in cancers where mTOR pathway alterations are common, including breast cancer, renal cell carcinoma, and certain brain tumors.